GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CorMedix CRMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.47

+2.82%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CorMedix

From its filings with the US Securities and Exchange Commission

SEC filings

CorMedix is based in Parsippany, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CRMD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $311.7m and net income of $163.1m. At that date it held total assets of $826.1m and shareholders' equity of $405.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 Mar 2010
Employees
191
Head office
389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

Leadership

Pay as last reported

  • Mr. Myron KaplanIndependent Chairman of the Board$210,564
  • Mr. Joseph TodiscoChief Executive Officer, Director, since 2022$2.4m
  • Ms. Susan BlumChief Financial Officer
  • Ms. Elizabeth HurlburtChief Operating Officer$1.1m
  • Ms. Beth KaufmanExecutive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
  • Ms. Erin MistryExecutive Vice President, Chief Commercial Officer$1.2m
  • Dr. Matthew DavidChief Business Officer$1.1m
  • Ms. Janet DillioneIndependent Director$159,564
  • Mr. Gregory DuncanIndependent Director$153,564
  • Dr. Alan DuntonIndependent Director$153,564
  • Mr. Steven LefkowitzIndependent Director, since 2011$174,564
  • Mr. Robert StewartIndependent Director$156,564

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
25
Environment
4
Social
33
Governance
37
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is focused on developing therapeutic products for life-threatening conditions.
  • Headquartered in Berkeley Heights, New Jersey with a clear product focus on DefenCath.
  • IPO occurred in 2010, indicating established market presence.

Weaknesses

  • Source description states 40 full-time employees, contradicting the provided 191 employees.
  • Product focus is limited to DefenCath with no mention of other products in the source.
  • Source description is untrusted and contains conflicting information.

Opportunities

  • Potential for DefenCath to address catheter-related infections in hemodialysis and other clinical settings.
  • Collaboration for taurolidine research could lead to new therapeutic applications.
  • Growth in pharmaceutical sector for life-threatening condition treatments.

Threats

  • Untrusted source description may lead to inaccurate information about company operations.
  • Employee count discrepancy could indicate internal reporting issues.
  • Limited product portfolio may increase vulnerability to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.